Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cleveland Clinic Drug Quality Dashboard Helps Guide Product Choices

Executive Summary

After realizing some generics don’t work, academic medical center screens quality by manufacturer. Other providers protest: It’s not our job.

You may also be interested in...



AAM Offers Drug Manufacturing Repatriation Plan … For A Price

Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.

Providers Support FDA Quest For Public Drug Manufacturing Quality Ratings

Agency agrees with those who prescribe and buy drugs on need to incentivize quality. Except providers want it yesterday.

Providers Support FDA Quest For Public Drug Manufacturing Quality Ratings

Agency agrees with those who prescribe and buy drugs on need to incentivize quality. Except providers want it yesterday.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel